InsidersTradesSigma
Follow the CONTINEUM THERAPEUTIC INC share price and the full directors' dealings record of the company, a listed equity based in United States. Shares are quoted on the US market, under the oversight of SEC (Form 4). Market capitalisation: €641.4m. The latest transaction was reported on 3 August 2026 (Notice of proposed sale (Form 144)). Among the most active insiders: Daniel Lorrain. Every trade is free.
Analysts rate CONTINEUM THERAPEUTIC INC Strong Buy (bullish), based on 7 analysts. Average price target: US$23.43.
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
1 of 1 declaration
CONTINEUM THERAPEUTIC INC is a company listed on the XNAS market, focused on developing innovative therapeutic solutions. It specializes in research and the development of treatments for various medical conditions.